Descartes-15

N/A

Report date: 2025/11/25 20:00:09

Base Information

Drug NameDescartes-15

Drug Alias NameDescartes-015Descartes-15

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-BCMA

TargetsB-cell maturation protein

Therapy Area/IndicationsSolid tumoursAutoimmune Diseases of the Nervous SystemMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCartesian Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesCartesian Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursAutoimmune Diseases of the Nervous System

Inactive IndicationsMultiple Myeloma

Other Information

ATC CodeN/A